Format

Send to

Choose Destination
Transl Androl Urol. 2017 Jun;6(3):483-489. doi: 10.21037/tau.2017.04.30.

MRI-fusion biopsy: the contemporary experience.

Author information

1
Division of Urology, Department of Surgery, NYU Lutheran Medical Center, NYU Langone Health System, New York, NY, USA.
2
Department of Radiology, NYU Lutheran Medical Center, NYU Langone Health System, New York, NY, USA.
3
Division of Urologic Oncology, Department of Urology, NYU Lutheran Medical Center, NYU Langone Health System, New York, NY, USA.

Abstract

Advancements in magnetic resonance imaging (MRI) and MRI-ultrasound (US)-fusion targeted biopsy have resulted in a paradigm shift in the diagnosis of prostate cancer by overcoming the limitations of systematic biopsy. Prebiopsy MRI and MRI-US-fusion biopsy results in an increased detection of clinically significant disease, reduction in the detection of indolent disease, and allows for tumor localization during targeted biopsy. With these advantages, we have adopted a prebiopsy MRI and MRI-US-fusion biopsy diagnostic care pathway for all men at risk for prostate cancer and have performed more than 1900 biopsies to date. Herein we present our institutional development of MRI-US-fusion biopsy and highlight our results in those men who have had a previous negative biopsy, no prior biopsy, and those with a prior cancer diagnosis who may be candidate for active surveillance. Risk stratification with biomarkers and nomograms may allow for further counseling on the need for biopsy and the risk of harboring clinically significant disease.

KEYWORDS:

MRI-ultrasound fusion; Pre-biopsy; magnetic resonance imaging (MRI); risk assessment; targeted biopsy

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center